Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Oct 21, 2021

SELL
$212.27 - $248.7 $209,510 - $245,466
-987 Closed
0 $0
Q2 2021

Jul 16, 2021

BUY
$233.58 - $259.14 $700 - $777
3 Added 0.3%
987 $242,000
Q1 2021

May 03, 2021

BUY
$221.91 - $258.6 $665 - $775
3 Added 0.31%
984 $245,000
Q4 2020

Feb 05, 2021

BUY
$216.38 - $257.67 $649 - $773
3 Added 0.31%
981 $226,000
Q3 2020

Oct 19, 2020

BUY
$234.65 - $260.95 $1,407 - $1,565
6 Added 0.62%
978 $249,000
Q2 2020

Jul 20, 2020

SELL
$197.81 - $242.74 $652,179 - $800,313
-3,297 Reduced 77.23%
972 $229,000
Q1 2020

Apr 24, 2020

BUY
$182.24 - $241.7 $546 - $725
3 Added 0.07%
4,269 $866,000
Q4 2019

Feb 10, 2020

SELL
$189.21 - $243.2 $406,423 - $522,393
-2,148 Reduced 33.49%
4,266 $1.03 Million
Q3 2019

Oct 21, 2019

BUY
$174.11 - $208.62 $348 - $417
2 Added 0.03%
6,414 $1.24 Million
Q2 2019

Aug 14, 2019

BUY
$166.7 - $195.41 $500 - $586
3 Added 0.05%
6,412 $1.18 Million
Q1 2019

Apr 23, 2019

BUY
$180.87 - $203.88 $542 - $611
3 Added 0.05%
6,409 $1.22 Million
Q4 2018

Feb 14, 2019

BUY
$178.4 - $208.25 $535 - $624
3 Added 0.05%
6,406 $1.25 Million
Q3 2018

Nov 08, 2018

BUY
$185.29 - $208.89 $370 - $417
2 Added 0.03%
6,403 $1.33 Million
Q2 2018

Aug 10, 2018

SELL
$166.05 - $186.51 $215,532 - $242,089
-1,298 Reduced 16.86%
6,401 $1.18 Million
Q1 2018

Apr 24, 2018

BUY
$169.43 - $198.0 $508 - $594
3 Added 0.04%
7,699 $1.31 Million
Q4 2017

Mar 02, 2018

SELL
$168.79 - $188.59 $33,420 - $37,340
-198 Reduced 2.51%
7,696 $1.34 Million
Q3 2017

Nov 17, 2017

BUY
$167.29 - $191.0 $334 - $382
2 Added 0.03%
7,894 $1.47 Million
Q2 2017

Aug 28, 2017

BUY
N/A
7,892
7,892 $1.36 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $171B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Aldebaran Financial Inc. Portfolio

Follow Aldebaran Financial Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aldebaran Financial Inc., based on Form 13F filings with the SEC.

News

Stay updated on Aldebaran Financial Inc. with notifications on news.